When was Samabriva founded?

Samabriva was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is Samabriva located?

Samabriva is headquartered in Amiens, France.

How many employees does Samabriva have?

As of Jun 30, 2026, the latest employee count at Samabriva is 12.

Is Samabriva a funded company?

Samabriva is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 12, 2023.

When was the latest funding round of Samabriva?

Samabriva's latest funding was a $***** Series A round on Dec 12, 2023, with participation from 2 investors.

Where does Samabriva rank among its competitors?

Samabriva ranks 71st amongst 128 active competitors, of which 44 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mirum Pharmaceuticals, which secured $68.5M in Jan, 2026.

Who are the top competitors of Samabriva?

Samabriva's top competitors include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Among them, Mirum Pharmaceuticals secured the most recent funding round in January, 2026.

Samabriva - 2026 Company Profile, Team, Funding & Competitors

Samabriva is a series A company based in Amiens (France), founded in 2018 by Alain Huriez. It operates as a Developer of enzymes replacement therapies for the treatment of lysosomal storage disorders. Samabriva has raised $4.3M in funding from Investsud and Noshaq. The company has 128 active competitors, including 44 funded and 42 that have exited. Its top competitors include companies like BioMarin Pharmaceutical, Ultragenyx and Pharvaris.

Company Details

Samabriva is developing biologics for the treatment of lysosomal storage disorders. The company is focused on developing enzymes replacement therapies (ERT). Its lead program, SAM-01 is an acid-sphingomyelinase recombinant enzyme for Niemann-Pick disease type A and B.

Website: samabriva.com
Email ID: *****@samabriva.com
Phone Number: +33 **********

Key Metrics

Founded Year

2018

Location

Amiens, France

Stage

Series A

Total Funding

$4.3M in 1 round

Latest Funding Round

Series A, Dec 12, 2023, $*****

Investors

Investsud & 3 more

Ranked

71^st among 128 active competitors

Employee Count

12 as on Jun 30, 2026

Similar Companies

Azafaros & 27 more

View Samabriva's full profile

Samabriva has raised a total funding of $4.3M over 1 round. Its latest funding round was a Series A round on Dec 12, 2023 for $*****. 2 investors participated in its latest round. Samabriva has 4 institutional investors.

Here is the list of recent funding rounds of Samabriva:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 12, 2023	3822056	Series A	3829010	6076142	1094901	9964184

Access funding benchmarks and valuations. Sign up today!

View details of Samabriva's funding rounds and investors

The founders of Samabriva is Alain Huriez.

Here are the details of Samabriva's key team members:

Alain Huriez: Co-Founder & Chairman of Samabriva.
Contact Info: 1 email address

View details of Samabriva's Founder profiles and Board Members

Samabriva's employee count trend

Samabriva has 12 employees as of Jun 26. Here is Samabriva's employee count trend over the years:

Uncover Samabriva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Samabriva include BioMarin Pharmaceutical, Ultragenyx and Pharvaris. Here is the list of Top 10 competitors of Samabriva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Temasek & 7 others	72/100
2nd	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Healthcap, F-Prime Capital & 10 others	69/100
3rd	Pharvaris 2015, Leiden (Netherlands), Public	Orally deliverable bradykinin B2 antagonists for hereditary angioedema	$164M	Life Sciences Partners, General Atlantic & 9 others	67/100
4th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Blindness.org & 7 others	65/100
5th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Deerfield & 9 others	64/100
6th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Wellington, Celgene & 10 others	63/100
7th	AIRNA 2021, Cambridge (United States), Series B	Developer of gene therapies for rare and common diseases	$245M	Forbion, Arch Venture Partners & 9 others	63/100
8th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Hercules Capital, Bristol-Myers Squibb & 11 others	62/100
9th	American Gene 2008, Rockville (United States), Series B	Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases	$53.1M	Ride wave ventures, Alumni Ventures & 3 others	60/100
10th	Cycle Pharma 2012, Cambridge (United Kingdom), Funding Raised	Small molecule drug reformulation and repurposing for orphan indications	-	robinson-family.ca, Michael A Tory Trust ... & 31 others	59/100
71st	Samabriva 2018, Amiens (France), Series A	Developer of enzymes replacement therapies for the treatment of lysosomal storage disorders	$4.3M	Noshaq, Investsud & 2 others	37/100